Compare ESGL & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ESGL | THAR |
|---|---|---|
| Founded | 1999 | 2017 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 169.6M | 193.3M |
| IPO Year | N/A | 2022 |
| Metric | ESGL | THAR |
|---|---|---|
| Price | $3.40 | $4.70 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 10.7K | ★ 1.2M |
| Earning Date | 03-03-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,328,277.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.90 | $0.95 |
| 52 Week High | $4.32 | $9.08 |
| Indicator | ESGL | THAR |
|---|---|---|
| Relative Strength Index (RSI) | 18.47 | 66.15 |
| Support Level | $3.19 | $2.71 |
| Resistance Level | $3.62 | $5.83 |
| Average True Range (ATR) | 0.19 | 0.50 |
| MACD | -0.04 | 0.21 |
| Stochastic Oscillator | 25.93 | 63.46 |
ESGL Holdings Ltd is a waste management, treatment, and recycling company involved in the collection and recycling of hazardous and non-hazardous industrial waste from customers such as pharmaceutical, semiconductor, petrochemical, and electroplating companies.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.